New GLP-1 Pill Delivers Up to 12% Weight Loss in 36 Weeks
An experimental GLP-1 pill helped people with obesity or overweight lose as much as 12.1% of their body weight in just 36 weeks.
A recent clinical trial has demonstrated the efficacy of an experimental GLP-1 pill, aleniglipron, in treating obesity and overweight. The study found that participants who took aleniglipron for 36 weeks experienced a significant reduction in body weight, with a mean weight loss of 12.1% compared to placebo. This finding is notable, as it suggests that aleniglipron may be a viable alternative to existing injectable GLP-1 medications such as Wegovy and Ozempic. Unlike these injectables, aleniglipron is a small molecule that can be taken once daily with or without food, which could potentially improve patient adherence and make it more accessible for widespread use. The ease of administration and potential for improved patient compliance are significant advantages of this new formulation. However, further research is needed to fully understand the mechanisms by which aleniglipron exerts its effects and to confirm these findings in larger, more diverse populations.